Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$11.11 USD
+0.56 (5.31%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $11.10 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for Cogent Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -192.41 | -140.24 | -72.27 | -74.81 | -31.83 |
Depreciation/Amortization & Depletion | -2.90 | -0.80 | 0.15 | 0.72 | 1.24 |
Net Change from Assets/Liabilities | 11.44 | 0.75 | 0.18 | -5.99 | -15.45 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 30.25 | 21.65 | 13.19 | 44.22 | 4.53 |
Net Cash From Operating Activities | -153.62 | -118.64 | -58.76 | -35.85 | -41.51 |
Property & Equipment | -2.80 | -6.86 | -1.72 | 8.42 | 0.17 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -95.03 | -117.86 | 0.00 | 0.00 | 22.99 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -97.82 | -124.72 | -1.72 | 8.42 | 23.16 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 163.54 | 163.56 | 38.06 | 232.20 | 0.11 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -0.09 | 0.00 | 0.00 |
Net Cash from Financing Activities | 163.54 | 163.56 | 37.98 | 232.20 | 0.11 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -87.91 | -79.80 | -22.51 | 204.77 | -18.25 |
Cash at Beginning of Period | 141.14 | 220.94 | 243.45 | 38.68 | 56.93 |
Cash at End of Period | 53.23 | 141.14 | 220.94 | 243.45 | 38.68 |
Diluted Net EPS | -2.42 | -2.39 | -1.87 | -16.17 | -4.16 |
Fiscal Year End for Cogent Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -117.30 | -58.35 | -192.41 | -138.05 | -82.66 |
Depreciation/Amortization & Depletion | 2.39 | -0.80 | -2.90 | 0.80 | -0.69 |
Net Change from Assets/Liabilities | -0.67 | -3.24 | 11.44 | 6.50 | -0.39 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 20.35 | 9.86 | 30.25 | 21.19 | 12.16 |
Net Cash From Operating Activities | -95.23 | -52.53 | -153.62 | -109.55 | -71.58 |
Property & Equipment | -0.22 | -0.07 | -2.80 | -2.48 | -2.36 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -83.36 | 1.11 | -95.03 | -105.83 | -15.42 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -83.58 | 1.04 | -97.82 | -108.31 | -17.78 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 213.80 | 214.06 | 163.54 | 163.54 | 162.54 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 213.80 | 214.06 | 163.54 | 163.54 | 162.54 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 34.99 | 162.57 | -87.91 | -54.33 | 73.18 |
Cash at Beginning of Period | 53.23 | 53.23 | 141.14 | 141.14 | 141.14 |
Cash at End of Period | 88.22 | 215.80 | 53.23 | 86.81 | 214.32 |
Diluted Net EPS | -0.59 | -0.62 | -0.64 | -0.64 | -0.59 |